Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q2 FY27 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Nov 4, 2026
Slide 1: Exchange filing cover letter: Investor Presentation
November 4, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Ref.: Disclosure
Slide 2: Earnings Presentation: Q2 FY27
Zydus Lifesciences Limited Earnings Presentation: Q2 FY27 4th November 2026
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q2 FY27: At a Glance
Q2 FY27: At a Glance Revenues from Highlights of Q2 FY27 R&D Operations ❑ Total revenues grew 29% YoY. Rs. 79,096 mn Rs. 6,573 mn ❑ Within Pharmaceutical business, 29% YoY 8.3% of revenues ➢ India branded formulations sustained market outperformance with 19% YoY growth during the quarter. EBITDA & M
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 80,170 79,096 72.4% 73.2% 74.0% 72.1 % 72.8% 75,870 68,645 56,107 57,772 57,552 61,232 50,282 44,327 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Total R&D (Rs. mn) and % t
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) Reported PAT (Rs. mn) Organic Capex (Rs. mn) 13,185 5,875 12,609 4,911 4,655 10,484 4,637 9,604 9,255 3,577 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Net Debt to EBITDA (x) Net Working Capital* (Rs. mn) 0.68 86,143 83,052 81,987 0.62
Slide 7: India Formulations business
India Formulations business Outperformed IPM across super specialty, chronic and acute segments Highlights for the quarter India Formulations Sales (Rs. mn) Q2 FY27 Revenue ▪ Branded business grew faster than the market with 18,844 Contribution 17,094 17,528 18,158 19% YoY growth. 15,926 ▪ Consisten
Slide 8: North America Formulations business
North America Formulations business Resilient performance on account of base business and branded portfolio Highlights for the quarter North America Formulations Sales (Rs. mn) Q2 FY27 Revenue US Generics Contribution 33,145 29,523 30,979 ▪ Base business continued to gain market share driven by 27,4
Slide 9: International Markets Formulations business
International Markets Formulations business Strong growth on the back of resilient demand across markets Highlights for the quarter IM Formulations Sales (Rs. mn) Q2 FY27 Revenue Contribution ▪ Growth was broad based in both Emerging markets 9,735 10,009 (EM) and Europe driven by strong demand and f
Slide 10: Consumer Wellness
Consumer Wellness Strengthening presence across markets Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q2 FY27 Revenue ▪ Domestic business grew 29% y-o-y supported by Contribution sustained positive momentum across categories driven 14,633 14,292 by steady urban recovery and improving r
Slide 11: Innovation and Other Updates
Innovation and Other Updates Innovation Updates NCE Research • Presented new analysis from Phase III clinical trial of Saroglitazar Magnesium in Primary Biliary Cholangitis (PBC) indication at the American College of Gastroenterology (ACG) 2026 Annual Meeting. • Successfully completed EVIDENCES-X gl
Slide 12: Zydus at a Glance
Zydus at a Glance 3rd 10 +$3 R&D Centers Largest generic Co. in US For NCE, APIs, Generics, Vaccines Global Revenues1 bn in terms of prescription3 Biosimilars, Wellness and Med-tech products Among 1st Revenues from Branded Approved product for ~57% In ~60% of product Business (Pharmaceutical, Top 3
Slide 13: ESG Updates
ESG Updates • Attained an ESG Rating of 71/100 by NSE Sustainability Ratings & Analytics • Progressed to the ‘Leader’ category i.e. Top 10% percentile band from the 2024 2025 2026 ‘Aspiring’ category in the previous year, demonstrating best-in-class ESG practices 65 70 71 • Ranked among Top 2* in In
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q2 Q2 YoY Q1 QoQ H1 H1 YoY Rs. mn FY27 FY26 gr. FY27 gr. FY27 FY26 gr. Total Income from Ops. 79,096 61,232 29.2% 80,170 -1.3% 1,59,266 1,26,969 25.4% Gross Contribution (GC) 57,552 44,327 29.8% 57,772 -0.4% 1,15,324 92,169 25.1% Gross Margin % 72.8% 72.
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q2 Q2 YoY H1 H1 YoY Rs. mn FY27 FY26 gr. % FY27 FY26 gr. % On operating transactions (above EBITDA line) a. Included in COGS 93 365 -75% 85 437 -80.5% b. Part of other operating expenses -1,366 -4,141 67% -1,935 -4,712 58.9% (shown separately) Total Exchange Rat
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra [email protected] +91-79-48040969 Registered Office: For more information, please visit: Zydus Corporate Park, Scheme No. 63, Survey No. 536, www.zyduslife.com Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway,